The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer
Jennifer Le Guévelou(Inserm), Dominique Pasquier(Centre National de la Recherche Scientifique), Paul Sargos, Thomas Zilli(University of Geneva), R. de Crevoisier(Centre Eugène Marquis), S. Supiot(Institut de Cancérologie de l'Ouest), Mario Terlizzi(Institut Gustave Roussy), Francesco Cuccia, Ronan Flippot(Institut Gustave Roussy), Giuseppe Ferrera, Jean‐Michel Hannoun‐Lévi(Centre Antoine Lacassagne)
Cited by 12
Related Papers
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
|Nature Reviews Clinical Oncology|2021|382
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
|Nature Communications|2021|167
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
|Journal of Clinical Oncology|2019|147
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus
|Radiotherapy and Oncology|2022|98